TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy

Dougall, William C. , Kurtulus, Sema, Smyth, Mark J. and Anderson, Ana C. (2017) TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy. Immunological Reviews, 276 1: 112-120. doi:10.1111/imr.12518


Author Dougall, William C.
Kurtulus, Sema
Smyth, Mark J.
Anderson, Ana C.
Title TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy
Journal name Immunological Reviews   Check publisher's open access policy
ISSN 1600-065X
0105-2896
Publication date 2017-03-01
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1111/imr.12518
Open Access Status Not yet assessed
Volume 276
Issue 1
Start page 112
End page 120
Total pages 9
Place of publication Hoboken, NJ, United States
Publisher Wiley-Blackwell Publishing
Collection year 2018
Language eng
Abstract While therapies targeting the co-inhibitory or immune checkpoint receptors PD-1 and CTLA-4 have shown remarkable success in many cancers, not all patients benefit from these therapies. This has catalyzed enormous interest in the targeting of other immune checkpoint receptors. In this regard, TIGIT and CD96 have recently entered the limelight as novel immune checkpoint receptor targets. TIGIT and CD96 together with the co-stimulatory receptor CD226 form a pathway that is analogous to the CD28/CTLA-4 pathway, in which shared ligands and differential receptor:ligand affinities fine-tune the immune response. Although the roles of TIGIT and CD96 as immune checkpoint receptors in T cell and natural killer cell biology are just beginning to be uncovered, accumulating data support the targeting of these receptors for improving anti-tumor immune responses. A clear understanding of the immune cell populations regulated by TIGIT and CD96 is key to the design of immunotherapies that target these receptors in combination with other existing immune checkpoint blockade therapies.
Keyword Anti-tumor immunity
Cancer immunotherapy
CD96
Checkpoint inhibitors
Co-inhibitory receptors
TIGIT
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: HERDC Pre-Audit
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 1 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 1 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 21 Mar 2017, 00:25:23 EST by Web Cron on behalf of Learning and Research Services (UQ Library)